港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

809.577

-3.509-0.43%

漲家數：13

跌家數：19

平家數：2

市盈率：- -

高：825.541

開：813.411

低：798.667

收：813.086

成交量：2.05億

成交額：54.14億

市值：4,853.88億

流通市值：4,411.11億

資料載入中...

“藥神”照進現實：中國原創抗癌藥榮獲上海市科技進步一等獎

榮昌生物(09995.HK)曾漲逾8% 上半年收入增近五成兼虧損收窄

阿斯达克财经

醫療器械板塊拐點或至，資金左側大舉增倉，醫療器械指數ETF（159898）近10日獲近1.2億元資金埋伏

港股異動｜$生物(000504)$醫藥股逆勢走高，$永泰生物-B(06978)$漲超5%，$加科思-B(01167)$、

老虎资讯综合

美藍醫藥申請一種安瓿瓶的激光切割裝置專利，便於將安瓿瓶本體輸送至切割頭處進行切割

國產創新藥靠BD大火醫療器械能否複製這一路徑？

8月26日再鼎醫藥在港交所公告上半年產品收入淨額同比增加15%至2.15億美元；研發開支同比減少4%至1.11億美元；虧

中藥上市公司半年報紛紛提及加大創新藥研發

再鼎醫藥(09688)發佈中期業績，總收入2.16億美元同比增加15.35%

醫藥板塊下跌特朗普再放狠話：下調藥品價格1400%至1500%

華麗家族股價持平 3億元增資創新藥企引關注

一心堂股價持平醫藥商業板塊成交額達2.66億元

信立泰股價微漲0.66% 化學製藥企業研發管線引關注

歌禮制藥-B(01672)8月25日發行2882萬股

新股消息 | 勁方醫藥通過港交所聆訊報告期內持續虧損

先瑞達醫療-B(06669)：外周可控機械解脱帶纖維毛彈簧圈的註冊申請獲中國國家藥品監督管理局批准

先瑞達醫療-B獲得中國國家藥監局批准其外周可控機械分離纖維彈簧圈產品

據港交所文件：勁方醫藥科技股份有限公司 - B通過港交所上市聆訊。

據港交所文件：勁方醫藥科技（上海）股份有限公司 - B通過港交所上市聆訊。

富國基金趙偉：創新藥行情才剛剛開始下一個10倍股可能來自自免和代謝領域

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":809.5766,"timestamp":1756194246216,"preClose":813.08563,"halted":0,"volume":204630382,"delay":0,"changeRate":-0.004316,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-3.509033,"latestTime":"08-26 15:44:07","open":813.4112,"high":825.54065,"low":798.6673,"amount":5414458334,"amplitude":0.033051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1756195800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"pbRate":6.722096,"peRate":-40.784235,"turnoverRate":0.007653,"increases":13,"decrements":19,"flats":1,"marketCap":485387683776,"floatMarketCap":441111455136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":825.54065,"amplitude":0.033051,"preClose":813.08563,"low":798.6673,"pbRate":"6.722096","latestPrice":809.5766,"volume":204630382,"delay":0,"open":813.4112,"prevYearClose":331.1933,"prevWeekClose":829.54,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":830.772,"twentyDayClose":768.836,"sixtyDayClose":474.737,"secType":"PLATE","market":"HK","turnoverRate":0.007653,"peRate":-40.784235,"marketCap":485387683776,"floatMarketCap":441111455136,"timestamp":1756194246216,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":13,"down":19,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562075270","title":"“藥神”照進現實：中國原創抗癌藥榮獲上海市科技進步一等獎","url":"https://stock-news.laohu8.com/highlight/detail?id=2562075270","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562075270?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 09:58","pubTimestamp":1756173532,"startTime":"0","endTime":"0","summary":"【“药神”照进现实：中国原创抗癌药荣获上海市科技进步一等奖】还记得电影《我不是药神》中天价抗癌药的困境吗？中国科学家用一场历时11年的“破冰之旅”，交出了一份现实版答卷——中国首个自主研发的高选择性抗癌药呋喹替尼，不仅让晚期结直肠癌患者生存期显著延长，更成功打入欧美日主流市场，成为全球抗癌药领域的“新标杆”。今天，这一由和记黄埔医药（上海）有限公司领衔的研发项目荣获上海市科技进步奖一等奖，标志着中国创新药从“跟跑”到“领跑”的历史性跨越。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508263494600446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1574","BK1588","00013","BK1161","06978","BK1587"],"gpt_icon":0},{"id":"2562827016","title":"榮昌生物(09995.HK)曾漲逾8% 上半年收入增近五成兼虧損收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2562827016","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562827016?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 09:47","pubTimestamp":1756172820,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 今日(26日)高开0.9%，早段曾升8.6%高见96.35元。现报94.5元，升6.54%，成交381.27万股，涉资3.56亿元。公司日前公布业绩，收益录得10.9亿人民币(下同)，按年增加47.6%，主要是公司自身免疫类商业化产品泰它西普以及抗肿瘤类商业化产品维迪西妥单抗销售增长强劲；亏损由上年同期7.8亿元，收窄至4.5亿元。不派息。(ss/)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-25 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1464324/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK0239","688331","BK1583","LU2148510915.USD","09995","LU2328871848.SGD","LU2488822045.USD","BK1161","LU1064131003.USD","LU1969619763.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2562277034","title":"醫療器械板塊拐點或至，資金左側大舉增倉，醫療器械指數ETF（159898）近10日獲近1.2億元資金埋伏","url":"https://stock-news.laohu8.com/highlight/detail?id=2562277034","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562277034?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 09:40","pubTimestamp":1756172413,"startTime":"0","endTime":"0","summary":"近期A股情绪高涨，上证指数连破3700、3800两道大关，成交额连续多日超2万亿元。根据深交所数据，医疗器械指数ETF已经连续10日获1.16亿元资金增仓，近20日这一数据为1.63亿元。基金最新规模4.1亿元刷新上市新高。不过从价格角度看，该ETF昨日收盘价0.616元，自2021年上市以来回撤幅度依然为四成。从基金多个阶段表现看，医疗器械指数ETF今年以来、近一年、近三年均跑赢业绩比较基准，超额能力居同指数ETF前列。","market":"hk","thumbnail":"https://imgcloud.jrjimg.cn/2025/08/20250826093933020.jpg","type":0,"news_type":0,"thumbnails":["https://imgcloud.jrjimg.cn/2025/08/20250826093933020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.jrj.com.cn/2025/08/26094052686268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09997","BK4550","BK1583","BK1574","BK4585","BK4588","09996","159898","BK1222","159883","BK1100","FDN"],"gpt_icon":0},{"id":"1139693123","title":"港股異動｜$生物(000504)$醫藥股逆勢走高，$永泰生物-B(06978)$漲超5%，$加科思-B(01167)$、","url":"https://stock-news.laohu8.com/highlight/detail?id=1139693123","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139693123?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 09:36","pubTimestamp":1756172181,"startTime":"0","endTime":"0","summary":"港股异动｜$生物(000504)$医药股逆势走高，$永泰生物-B(06978)$涨超5%，$加科思-B(01167)$、$荣昌生物(09995)$涨超4%，$歌礼制药-B(01672)$涨超2%.","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","09939","01672","09995","LU2328871848.SGD","BK1515","BK4614","LU1969619763.USD","01167","YANG","BK1583","BK1574","01477","BK1161","07226","06978","HSCEI","BK1191"],"gpt_icon":0},{"id":"2562927212","title":"美藍醫藥申請一種安瓿瓶的激光切割裝置專利，便於將安瓿瓶本體輸送至切割頭處進行切割","url":"https://stock-news.laohu8.com/highlight/detail?id=2562927212","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562927212?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 09:06","pubTimestamp":1756170381,"startTime":"0","endTime":"0","summary":"金融界2025年8月26日消息，国家知识产权局信息显示，美蓝 医药科技有限公司申请一项名为“一种安瓿瓶的激光切割装置”的专利，公开号CN120533315A，申请日期为2025年06月。通过天眼查大数据分析，美蓝（杭州）医药科技有限公司共对外投资了8家企业，财产线索方面有商标信息4条，专利信息136条，此外企业还拥有行政许可7个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26090652685205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1161","BK1574","159938","09939"],"gpt_icon":0},{"id":"2562027949","title":"國產創新藥靠BD大火 醫療器械能否複製這一路徑？","url":"https://stock-news.laohu8.com/highlight/detail?id=2562027949","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562027949?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 07:52","pubTimestamp":1756165922,"startTime":"0","endTime":"0","summary":"【国产创新药靠BD大火 医疗器械能否复制这一路径？】“BD（业务发展）是个大热点，我们最近的一次线上会起码有一半时间，分析师都在问相关话题。”近期，一位国内医疗器械行业人士向澎湃新闻记者发出了这样的感慨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508263494220491.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508263494220491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1100","BK1222","BK1574","BK1161","09997","09996","BK1583"],"gpt_icon":0},{"id":"2562276974","title":"8月26日再鼎醫藥在港交所公告上半年產品收入淨額同比增加15%至2.15億美元；研發開支同比減少4%至1.11億美元；虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2562276974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562276974?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 07:09","pubTimestamp":1756163380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","BK1574","BK4139","BK1588","HEXmain","BK4526","BK4585","BK4531","BK4588","BK1161","BK4548","ZLAB","LU2488822045.USD"],"gpt_icon":0},{"id":"2562764812","title":"中藥上市公司半年報紛紛提及加大創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2562764812","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562764812?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 07:09","pubTimestamp":1756163340,"startTime":"0","endTime":"0","summary":"　　同花顺数据显示，截至8月25日，共计27家中药上市公司发布2025年半年度业绩报告。其中，10家上半年营业收入实现正增长，增幅超10%的有6家；13家归属于上市公司股东的净利润实现正增长，占比约48%。　　当前，我国医药行业正处于从传统医药向创新医药转型的关键发展阶段。　　从已披露的半年报看，上半年中药上市公司经营“喜忧参半”，业绩分化明显。　　加大创新药研发也是中药上市公司在半年报中频频提及的重要战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-08-26/doc-infnhekr6991554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2562276863","title":"再鼎醫藥(09688)發佈中期業績，總收入2.16億美元 同比增加15.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562276863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562276863?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 06:45","pubTimestamp":1756161948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布2025年中期业绩，该集团取得总收入2.16亿美元，同比增加15.35%;亏损净额8916.5万美元，同比减少33.33%;每股亏损0.08美元。产品收入净额增加2750万美元(或15%)至2.15亿美元，主要由于卫伟迦的销售额受疗程延长及市场渗透率提升的推动而增长、纽再乐的销售额受市场覆盖范围及渗透率提升的推动而增长及自2024年第四季度起上市的鼎优乐的销售额增长。研发开支减少490万美元(或4%)至1.11亿美元，主要由于持续的资源优化及效率提升令人员和临床试验成本减少，部分被许可费增加所抵销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)发布中期业绩，总收入2.16亿美元 同比增加15.35%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4531","BK4548","BK4585","LU2488822045.USD","BK1588","09688","BK4139","BK1574","BK4526","BK4588","ZLAB"],"gpt_icon":0},{"id":"2562275654","title":"醫藥板塊下跌 特朗普再放狠話：下調藥品價格1400%至1500%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562275654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562275654?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 06:00","pubTimestamp":1756159200,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","159938","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2562221405","title":"華麗家族股價持平 3億元增資創新藥企引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2562221405","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562221405?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 01:49","pubTimestamp":1756144177,"startTime":"0","endTime":"0","summary":"截至8月25日收盘，华丽家族股价报3.15元，与前一交易日持平。当日成交额达4.84亿元，换手率为9.61%。华丽家族主营业务为房地产开发，同时涉及石墨烯等新材料领域。近期公司公告拟以不超过3亿元现金认购海和药物5%-8.09%股份，跨界布局创新药领域。8月10日公司公告显示，此次投资标的海和药物已有3款创新药上市，包括治疗非小细胞肺癌的谷美替尼片等产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26014952680099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0077","600503","159992","BK0188","BK0273","BK0061","BK0028","BK0012","06978","BK1574","BK0131"],"gpt_icon":0},{"id":"2562229205","title":"一心堂股價持平 醫藥商業板塊成交額達2.66億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562229205","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562229205?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 01:19","pubTimestamp":1756142343,"startTime":"0","endTime":"0","summary":"截至2025年8月25日收盘，一心堂股价报15.16元，与前一交易日持平。当日成交量为176026手，成交金额2.66亿元，换手率为4.43%。一心堂属于医药商业板块，同时涉及云南板块、内贸流通等概念。公司主要从事医药零售连锁和医药批发业务，在云南省内具有较高的市场占有率。8月25日主力资金净流出2656.6万元，占流通市值的0.44%。近五个交易日累计净流出4280.52万元，占流通市值的0.71%。风险提示：股市有风险，投资需谨慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26011952680008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1161","002727","09939","159938","BK0209","BK0097","LU1969619763.USD","BK0077","LU2328871848.SGD","BK1574"],"gpt_icon":0},{"id":"2562226791","title":"信立泰股價微漲0.66% 化學製藥企業研發管線引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2562226791","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562226791?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 00:31","pubTimestamp":1756139514,"startTime":"0","endTime":"0","summary":"信立泰最新股价报53.09元，较前一交易日上涨0.35元。盘中最高触及54.40元，最低下探52.11元，全天成交金额达5.04亿元，换手率为0.85%。该公司主营业务为化学制药，专注于心血管、抗感染、抗肿瘤等领域的创新药物研发。作为深圳特区企业，信立泰已建立起从原料药到制剂的全产业链布局，拥有多项核心专利技术。从资金流向来看，8月25日主力资金净流出5214.05万元，近五个交易日累计净流出8836.77万元。当前公司总市值591.86亿元，市盈率为81.06倍。风险提示：股市有风险，投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26003152679708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0196","BK0187","BK1574","BK1191","BK0239","BK0028","002294","01477","BK0188","BK0183"],"gpt_icon":0},{"id":"2562264247","title":"歌禮制藥-B(01672)8月25日發行2882萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562264247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562264247?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:44","pubTimestamp":1756129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议, 根据一般授权配发及发行2882万股新股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01672","BK1574","BK1161","01477","BK1515"],"gpt_icon":0},{"id":"2562426002","title":"新股消息 | 勁方醫藥通過港交所聆訊 報告期內持續虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426002","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562426002?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:14","pubTimestamp":1756127690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月25日披露，劲方医药科技(上海)股份有限公司通过港交所上市聆讯，中信证券为其独家保荐人。公司已在中国启动针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验的II期部分。KRAS G12D是最常见的致癌基因KRAS突变，尚无获批的治疗方案可用。财务方面，于2023年度、2024年度及2025年截至4月30日止四个月，劲方医药现收入分别约为7373.4万元、1.05亿元、8214.9万元人民币；年/期内亏损分别约为5.08亿元、6.78亿元、6662.4万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","09939","HEXmain","BK1574","BK1161"],"gpt_icon":0},{"id":"2562564242","title":"先瑞達醫療-B(06669)：外周可控機械解脱帶纖維毛彈簧圈的註冊申請獲中國國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2562564242","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562564242?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:12","pubTimestamp":1756127538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B(06669)发布公告，于2025年8月22日，集团收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧圈的注册批准。本产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。本产品采用可控解脱机制，确保弹簧圈释放过程稳定、精准，提升了操作的可控性和安全性。此外，产品具有2D和3D两种结构可选择，能够广泛适配临床需求。公司将适时在中国开展营销活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1587","BK1574","06669"],"gpt_icon":0},{"id":"1172020994","title":"先瑞達醫療-B獲得中國國家藥監局批准其外周可控機械分離纖維彈簧圈產品","url":"https://stock-news.laohu8.com/highlight/detail?id=1172020994","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172020994?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:01","pubTimestamp":1756126890,"startTime":"0","endTime":"0","summary":"先瑞达医疗-B宣布，公司的外周可控机械分离纤维弹簧圈产品已获得中国国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","BK1587","06669"],"gpt_icon":0},{"id":"2562241464","title":"據港交所文件：勁方醫藥科技股份有限公司 - B通過港交所上市聆訊。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562241464","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562241464?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 20:27","pubTimestamp":1756124848,"startTime":"0","endTime":"0","summary":"据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25202752675572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","159938","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"2562524166","title":"據港交所文件：勁方醫藥科技（上海）股份有限公司 - B通過港交所上市聆訊。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524166?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 20:22","pubTimestamp":1756124521,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","BK1161","159938","BK1574","HEXmain"],"gpt_icon":0},{"id":"2562524658","title":"富國基金趙偉：創新藥行情才剛剛開始 下一個10倍股可能來自自免和代謝領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524658?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 19:27","pubTimestamp":1756121233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，富国基金基金经理赵伟分享了对医药市场尤其对创新药的看法。赵伟指出，创新药现在是起点，刚刚开始。他认为自免和代谢领域机会很大。从今年、明年开始，国内获批新药的数量还会持续增长，未来中国创新药的获批量很可能会迎来井喷。此外，这轮创新药行情的最核心逻辑是出海。肿瘤是美国和中国最大的治疗领域。赵伟表示，未来投资要看胜率和赔率，真正的大单品可能是下一个十倍股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","159992","06978"],"gpt_icon":0}],"pageSize":20,"totalPage":23,"pageCount":2,"totalSize":450,"code":"91000000","status":"200"}]}}